|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A review of CETP and its rela- tion to atherosclerosis 显示文摘 | Greetje J Anke H Erik S | 2004 | J Lipid Res2004，45，11： | 1 |
| 2 | Perceived Social Support and Early Adolescents’ Achievement: The Mediational Roles of Motivational Beliefs and Emotions显示文摘 | Wondimu Ahmed Alexander Minnaert Greetje Werf Hans Kuyper | 2010 | Journal of Youth and Adolescence2010，，1： | 1 |
| 3 | Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II Dyslipidemia显示文摘 | Jan Albert Kuivenhoven Greetje J. de Grooth Hitoshi Kawamura Anke H. Klerkx Francois Wilhelm Mieke D. Trip John J.P. Kastelein | 2005 | The American Journal of Cardiology2005，，9： | 1 |
| 4 | Towards non‐invasive monitoring of pathogen–host interactions during C andida albicans biofilm formation using in vivo bioluminescence显示文摘 | Greetje Vande Velde Soňa Kucharíková Sanne Schrevens Uwe Himmelreich Patrick Van Dijck | 2014 | Cell Microbiol2014，，1： | 1 |
| 5 | Trichostatin A, a critical factor in maintaining the functional differentiation of primary cultured rat hepa- tocytes显示文摘 | Tom H Peggy P Greetje E | 2007 | Toxicol App Pharmaco12007，218，： | 1 |
| 6 | Teacher Educators Modelling Their Teachers ?显示文摘 | GREETJE T | 2009 | European Journal of Teacher Education2009，，3： | 1 |
| 7 | Trichostatin A, a critical factor in maintaining the functional differentiation of primary cultured rat hepatocytes 显示文摘 | Tom H Peggy P Greetje E | 2007 | Toxicol Appl Pharmacol2007，218，： | 1 |
| 8 | Evaluation of Cladribine treatment in refractory celiac disease type Ⅱ显示文摘AIM: To evaluate cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in refractory celiac disease (RCD) Ⅱ. METHODS: An open-label cohort-study of RCD Ⅱ patients treated with 2-CdA was performed between 2000 and 2010. Survival rate, enteropathy associated T-cell lymphoma (EATL) occurrence, clinical course, and histological and immunological response rates were evaluated. RESULTS: Overall, 32 patients were included with a median follow-up of 31 mo. Eighteen patients responded well to 2-CdA. Patients responsive to 2-CdA had a statistically significant increased survival compared to those who were unresponsive. The overall 3- and 5-year survival was 83% in the responder and 63% and 22% in the non-responder group, respectively. The overall 2-year clinical, histological and immunological response rates were 81%, 47% and 41%, respectively. Progression into EATL was reported in 16%, all of these patients died. CONCLUSION: Treatment of RCD Ⅱ with 2-CdA holds promise, showing excellent clinical and histological response rates, and probably less frequent transition into EATL. | Greetje J Tack Wieke HM Verbeek Abdul Al-Toma Dirk J Kuik Marco WJ Schreurs Otto Visser Chris JJ Mulder | 2011 | World Journal of Gastroenterology2011，17，4： | 1 |
| 9 | Emotions, self - regulated learning and achievement in mathematics: A growth curve analysis 显示文摘 | Wondimu A Greetje W Hans K | 2013 | Journal of Educational Psychology2013，，1： | 1 |
| 10 | Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study显示文摘AIM:To assesses the safety and efficacy of Aspergillus niger prolyl endoprotease(AN-PEP)to mitigate the im-munogenic effects of gluten in celiac patients.METHODS:Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet(GFD)resulting in normalised antibodies and mucosal healing classified as Marsh 0 orⅠwere included.In a randomised double-blind placebo-controlled pilot study,patients consumed toast(approximately 7 g/d gluten)with AN-PEP for 2 wk(safety phase).After a 2-wk washout period with adherence of the usual GFD,14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk(efficacy phase).Measurements at baseline included complaints,quality-of-life,serum antibodies,immunophenotyping of T-cells and duodenal mucosa immunohistology.Furthermore,serum and quality of life questionnaires were collected during and after the safety,washout and efficacy phase.Duodenal biopsies were collected after the safety phase and after the efficacy phase.A change in histological evaluation according to the modified Marsh classification was the primary endpoint.RESULTS:In total,16 adults were enrolled in the study.No serious adverse events occurred during the trial and no patients withdrew during the trial.The mean score for the gastrointestinal subcategory of the celiac disease quality(CDQ)was relatively high throughout the study,indicating that AN-PEP was well tolerated.In the efficacy phase,the CDQ scores of patients consuming gluten with placebo or gluten with AN-PEP did not significantly deteriorate and moreover no differences between the groups were observed.During the efficacy phase,neither the placebo nor the AN-PEP group developed significant antibody titers.The IgA-EM concentrations remained negative in both groups.Two patients were excluded from entering the efficacy phase as their mucosa showed an increase oftwo Marsh steps after the safety phase,yet with undetectable serum antibodies,while 14 patients were considered histologically stable on gluten with AN-PEP.Also after the efficacy phase,no significant deterioration was observed regarding immunohistological and flow cytometric evaluation in the group consuming placebo compared to the group receiving AN-PEP.Furthermore,IgA-tTG deposit staining increased after 2 wk of gluten compared to baseline in four out of seven patients on placebo.In the seven patients receiving AN-PEP,one patient showed increased and one showed decreased IgA-tTG deposits.CONCLUSION:AN-PEP appears to be well tolerated.However,the primary endpoint was not met due to lack of clinical deterioration upon placebo,impeding an effect of AN-PEP. | Greetje J Tack Jolanda MW van de Water Maaike J Bruins Engelina MC Kooy-Winkelaar Jeroen van Bergen Petra Bonnet Anita CE Vreugdenhil Ilma Korponay-Szabo Luppo Edens B Mary E von Blomberg Marco WJ Schreurs Chris J Mulder Frits Koning | 2013 | World Journal of Gastroenterology2013，19，35： | 1 |
| 11 | Perinatal death in two sibs with infantile cortical hyperostosis (Caffey disease)显示文摘 | Limie M Muller M | 1995 | Am J Med Genet1995，59，1： | 1 |
| 12 | Diversity in biofilm formation and production of curli fimbriae and cellulose of Salmonella typhimurium strains of different origin in high and low nutrient medium 显示文摘 | Greetje A A Castelijn Stijn van der Veen Marcel H Zwietering Roy Moezelaar Tjakko Abee | 2012 | Biofouling2012，28，1： | 1 |
| 13 | Targeted STAT1 therapy for LZTR1-driven peripheral nerve sheath tumor显示文摘Dear Editor,Schwannomas are peripheral nervous system tumors that cause chronic pain,numbness,and potentially lifethreatening organ dysfunction.Surgery is a conventional treatment for schwannoma patients.However,those who undergo surgery may experience neurological deficits.Moreover,the management of schwannomas can be problematic due to their unpredictable growth.Thus,there is a pressing need for nonsurgical treatments to manage both tumor growth and pain control. | Tonci Ivanisevic Mikhail Steklov Benoit Lechat Christopher Cawthorne Willy Gsell Greetje Vande Velde Christophe Deroose Koen Van Laere Uwe Himmelreich Raj N Sewduth Anna A Sablina | 2023 | Cancer Communications2023，43，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员